ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure: "ERADICATE-HF"
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ERADICATE-HF
- 31 Aug 2018 Biomarkers information updated
- 01 May 2018 Planned initiation date changed from 1 Mar 2018 to 7 May 2018.
- 02 Feb 2018 New trial record